Developing Multidisciplinary Clinics for Neuromuscular Care and Research

Overview

Journal Muscle Nerve

Date 2017 Jun 21

PMID 28632945

Citations 20

Authors

Sabrina Paganoni

Katie Nicholson

Fawn Leigh

Kathryn Swoboda

David Chad

Kristin Drake

Kellen Haley

Merit Cudkowicz

James D Berry

Affiliations

Soon will be listed here.

Abstract

Multidisciplinary care is considered the standard of care for both adult and pediatric neuromuscular disorders and has been associated with improved quality of life, resource utilization, and health outcomes. Multidisciplinary care is delivered in multidisciplinary clinics that coordinate care across multiple specialties by reducing travel burden and streamlining care. In addition, the multidisciplinary care setting facilitates the integration of clinical research, patient advocacy, and care innovation (e.g., telehealth). Yet, multidisciplinary care requires substantial commitment of staff time and resources. We calculated personnel costs in our ALS clinic in 2015 and found an average cost per patient visit of $580, of which only 45% was covered by insurance reimbursement. In this review, we will describe classic and emerging concepts in multidisciplinary care models for adult and pediatric neuromuscular disease. We will then explore the financial impact of multidisciplinary care with emphasis on sustainability and metrics to demonstrate quality and value. Muscle Nerve 56: 848-858, 2017.

Citing Articles

Health Care Delivery and Financial Considerations in Amyotrophic Lateral Sclerosis Clinics: A Survey of Clinic Directors.

Hollin I, Giler G, Heiman-Patterson T Neurology. 2025; 104(4):e210015.

PMID: 39883905 PMC: 11781782. DOI: 10.1212/WNL.0000000000210015.

Priorities and Recommendations to Make ALS a Livable Disease Emanating from the 2024 National Academies of Sciences, Engineering, and Medicine Report Living with ALS.

Howard I, Babu S, Carter C, Sakowski S, Kurent J, Cudkowicz M Ann Neurol. 2024; 96(6):1035-1039.

PMID: 39390661 PMC: 11563851. DOI: 10.1002/ana.27097.

A Quality Improvement Project to Improve After-visit Summary Patient Instructions in a Pediatric Multidisciplinary Neuromuscular Program.

de Pins A, Adu-Amankwah D, Shadman K, Hess S, Elaiho C, Butler L Pediatr Qual Saf. 2024; 9(4):e743.

PMID: 38993270 PMC: 11236396. DOI: 10.1097/pq9.0000000000000743.

Carbon Footprint Reduction Associated With Multidisciplinary Pediatric Airway Clinics: A Program Evaluation Study.

Zgardau A, Hathi K, Fowler J, Mullowney T, Price A, Husein M OTO Open. 2024; 8(3):e167.

PMID: 38974174 PMC: 11222738. DOI: 10.1002/oto2.167.

The value of knowing: preferences for genetic testing to diagnose rare muscle diseases.

Mansfield C, Boeri M, Coulter J, Baranowski E, Sparks S, Haack K Orphanet J Rare Dis. 2024; 19(1):173.

PMID: 38649872 PMC: 11036564. DOI: 10.1186/s13023-024-03160-7.

References

Warman Chardon J, Beaulieu C, Hartley T, Boycott K, Dyment D . Axons to Exons: the Molecular Diagnosis of Rare Neurological Diseases by Next-Generation Sequencing. Curr Neurol Neurosci Rep. 2015; 15(9):64. DOI: 10.1007/s11910-015-0584-7. View

Ness K, Apkon S . Bone health in children with neuromuscular disorders. J Pediatr Rehabil Med. 2014; 7(2):133-42. DOI: 10.3233/PRM-140282. View

Schroth M . Special considerations in the respiratory management of spinal muscular atrophy. Pediatrics. 2009; 123 Suppl 4:S245-9. DOI: 10.1542/peds.2008-2952K. View

Kassardjian C, Amato A, Boon A, Childers M, Klein C . The utility of genetic testing in neuromuscular disease: A consensus statement from the AANEM on the clinical utility of genetic testing in diagnosis of neuromuscular disease. Muscle Nerve. 2016; 54(6):1007-1009. DOI: 10.1002/mus.25387. View

Pinto A, Almeida J, Pinto S, Pereira J, Oliveira A, de Carvalho M . Home telemonitoring of non-invasive ventilation decreases healthcare utilisation in a prospective controlled trial of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2010; 81(11):1238-42. DOI: 10.1136/jnnp.2010.206680. View

Bushby K, Finkel R, Birnkrant D, Case L, Clemens P, Cripe L . Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2009; 9(2):177-89. DOI: 10.1016/S1474-4422(09)70272-8. View

Wang C, Finkel R, Bertini E, Schroth M, Simonds A, Wong B . Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007; 22(8):1027-49. DOI: 10.1177/0883073807305788. View

Henderson R, Hutchinson N, Douglas J, Douglas C . Telehealth for motor neurone disease. Med J Aust. 2014; 201(1):31. DOI: 10.5694/mja14.00170. View

Lechtzin N, Wiener C, Clawson L, Chaudhry V, Diette G . Hospitalization in amyotrophic lateral sclerosis: causes, costs, and outcomes. Neurology. 2001; 56(6):753-7. DOI: 10.1212/wnl.56.6.753. View

10.

Boylan K, Levine T, Lomen-Hoerth C, Lyon M, Maginnis K, Callas P . Prospective study of cost of care at multidisciplinary ALS centers adhering to American Academy of Neurology (AAN) ALS practice parameters. Amyotroph Lateral Scler Frontotemporal Degener. 2015; 17(1-2):119-27. DOI: 10.3109/21678421.2015.1091478. View

11.

Birnkrant D, Bushby K, Amin R, Bach J, Benditt J, Eagle M . The respiratory management of patients with duchenne muscular dystrophy: a DMD care considerations working group specialty article. Pediatr Pulmonol. 2010; 45(8):739-48. DOI: 10.1002/ppul.21254. View

12.

Gladman M, Dharamshi C, Zinman L . Economic burden of amyotrophic lateral sclerosis: a Canadian study of out-of-pocket expenses. Amyotroph Lateral Scler Frontotemporal Degener. 2014; 15(5-6):426-32. DOI: 10.3109/21678421.2014.932382. View

13.

Panitch H . Respiratory issues in the management of children with neuromuscular disease. Respir Care. 2006; 51(8):885-93. View

14.

Farrar M, Park S, Vucic S, Carey K, Turner B, Gillingwater T . Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol. 2016; 81(3):355-368. PMC: 5396275. DOI: 10.1002/ana.24864. View

15.

Hsu D . Cardiac manifestations of neuromuscular disorders in children. Paediatr Respir Rev. 2010; 11(1):35-8. DOI: 10.1016/j.prrv.2009.10.004. View

16.

Stephens H, Young J, Felgoise S, Simmons Z . A Qualitative Study of Multidisciplinary ALS Clinic Use in the United States. Amyotroph Lateral Scler Frontotemporal Degener. 2015; 17(1-2):55-61. DOI: 10.3109/21678421.2015.1069851. View

17.

Palladino A, Passamano L, Taglia A, DAmbrosio P, Scutifero M, Cecio M . Cardiac involvement in patients with spinal muscular atrophies. Acta Myol. 2012; 30(3):175-8. PMC: 3298107. View

18.

Schara U, Mortier , Mortier W . Long-Term Steroid Therapy in Duchenne Muscular Dystrophy-Positive Results versus Side Effects. J Clin Neuromuscul Dis. 2008; 2(4):179-83. DOI: 10.1097/00131402-200106000-00002. View

19.

Schepelmann K, Winter Y, Spottke A, Claus D, Grothe C, Schroder R . Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurol. 2009; 257(1):15-23. DOI: 10.1007/s00415-009-5256-6. View

20.

Vajda A, McLaughlin R, Heverin M, Thorpe O, Abrahams S, Al-Chalabi A . Genetic testing in ALS: A survey of current practices. Neurology. 2017; 88(10):991-999. PMC: 5333513. DOI: 10.1212/WNL.0000000000003686. View